Literature DB >> 19603525

Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways.

Hanne-Sofie S Dahlback1, Petter Brandal, Torstein R Meling, Ludmila Gorunova, David Scheie, Sverre Heim.   

Abstract

Screening the whole glioblastoma multiforme (GBM) genome for aberrations is a good starting point when looking for molecular markers that could potentially stratify patients according to prognosis and optimal treatment. We investigated 80 primary untreated GBM using both G-banding analysis and high-resolution comparative genomic hybridization (HR-CGH). Abnormal karyotypes were found in 83% of the tumors. The most common numerical chromosome aberrations were +7, -10, -13, -14, -15, +20, and -22. Structural abnormalities most commonly involved chromosomes 1 and 3, and the short arm of chromosome 9. HR-CGH verified these findings and revealed additional frequent losses at 1p34-36, 6q22-27, and 19q12-13 and gains of 3q26 and 12q13-15. Although most karyotypes and gain/loss patterns were complex, there was also a distinct subset of tumors displaying simple karyotypic changes only. There was a statistically significant association between trisomy 7 and monosomy 10, and also between +7/-10 as putative primary aberrations and secondary losses of 1p, 9p, 13q, and 22q. The low number of tumors in the rarer histological tumor subgroups precludes definite conclusions, but there did not seem to be any clear-cut cytogenetic-pathological correlations, perhaps with the exception of ring chromosomes in giant cell glioblastomas. Our findings demonstrate that although GBM is a pathogenetically very heterogeneous group of diseases, distinct genomic aberration patterns exist. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19603525     DOI: 10.1002/gcc.20690

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  17 in total

1.  Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.

Authors:  Inês Crespo; Ana Luísa Vital; Ana Belen Nieto; Olinda Rebelo; Hermínio Tão; Maria Celeste Lopes; Catarina Resende Oliveira; Pim J French; Alberto Orfao; María Dolores Tabernero
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

2.  Disruption of transient receptor potential canonical channel 1 causes incomplete cytokinesis and slows the growth of human malignant gliomas.

Authors:  Valerie C Bomben; Harald Sontheimer
Journal:  Glia       Date:  2010-08       Impact factor: 7.452

3.  Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Authors:  Gautam Prasad; Theo Sottero; Xiaodong Yang; Sabine Mueller; C David James; William A Weiss; Mei-Yin Polley; Tomoko Ozawa; Mitchel S Berger; Dana T Aftab; Michael D Prados; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2011-02-11       Impact factor: 12.300

4.  Network modeling of the transcriptional effects of copy number aberrations in glioblastoma.

Authors:  Rebecka Jörnsten; Tobias Abenius; Teresia Kling; Linnéa Schmidt; Erik Johansson; Torbjörn E M Nordling; Bodil Nordlander; Chris Sander; Peter Gennemark; Keiko Funa; Björn Nilsson; Linda Lindahl; Sven Nelander
Journal:  Mol Syst Biol       Date:  2011-04-26       Impact factor: 11.429

5.  Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.

Authors:  Brad Davis; Yaoqing Shen; Candice C Poon; H Artee Luchman; Owen D Stechishin; Carly S Pontifex; Wei Wu; John J Kelly; Michael D Blough
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

6.  Characterization of a new glioblastoma cell line, GB-val4, with unusual TP53 mutation.

Authors:  Lisandra Muñoz-Hidalgo; Teresa San-Miguel; Javier Megías; Rosario Gil-Benso; Miguel Cerdá-Nicolás; Concha López-Ginés
Journal:  Hum Cell       Date:  2019-08-06       Impact factor: 4.174

7.  Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels.

Authors:  Inês Crespo; Hermínio Tão; Ana Belen Nieto; Olinda Rebelo; Patrícia Domingues; Ana Luísa Vital; Maria del Carmen Patino; Marcos Barbosa; Maria Celeste Lopes; Catarina Resende Oliveira; Alberto Orfao; María Dolores Tabernero
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

8.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.

Authors:  Craig H Mermel; Steven E Schumacher; Barbara Hill; Matthew L Meyerson; Rameen Beroukhim; Gad Getz
Journal:  Genome Biol       Date:  2011-04-28       Impact factor: 13.583

Review 9.  Recent advances in the molecular understanding of glioblastoma.

Authors:  Fonnet E Bleeker; Remco J Molenaar; Sieger Leenstra
Journal:  J Neurooncol       Date:  2012-01-20       Impact factor: 4.130

10.  Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study.

Authors:  Annunziato Mangiola; Nathalie Saulnier; Pasquale De Bonis; Daniela Orteschi; Gigliola Sica; Gina Lama; Benedetta Ludovica Pettorini; Giovanni Sabatino; Marcella Zollino; Libero Lauriola; Anna Colabianchi; Gabriella Proietti; Gyula Kovacs; Giulio Maira; Carmelo Anile
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.